Alectinib - Usual
IND 168453 to be IND EXEMPT
Phase 3 small_molecule active
Quick answer
Alectinib - Usual for ALK-Positive Non-Small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lxo Ireland Designated Activity Company
- Indication
- ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active